In summary, three baseline predictive models for heart failure in breast cancer patients have been composed, and the one developed by Ezaz et al. in HER2-positive breast cancer patients [15] was validated in highly selected external cohort with moderate performance [16]. This evidence concerns the gene ERBB2 and heart failure.